New hope for kids with stubborn hives: dupilumab studied
NCT ID NCT05526521
First seen Nov 19, 2025 · Last updated May 13, 2026 · Updated 27 times
Summary
This study tested the safety and drug levels of dupilumab in 15 children aged 2 to 12 with chronic spontaneous urticaria (CSU), also known as long-lasting hives, that did not get better with standard antihistamines. The children received dupilumab for 24 weeks and were monitored for side effects and how the drug moved through their bodies. The goal was to see if this treatment could help control their symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Childrens Health Physicians Site Number : 8400017
Hawthorne, New York, 10532, United States
-
Childrens Hospital Medical Center of Akron- Site Number : 8400020
Akron, Ohio, 44308, United States
-
Cincinnati Children's Hospital Medical Center - PIN- Site Number : 8400001
Cincinnati, Ohio, 45229-3026, United States
-
Columbia University Irving Medical Center Site Number : 8400003
New York, New York, 10032, United States
-
Investigational Site Number : 1240001
Montreal, Quebec, H4A 3J1, Canada
-
Investigational Site Number : 1240007
Hamilton, Ontario, L8S1G5, Canada
-
Investigational Site Number : 1240009
Calgary, Alberta, T2W 4X9, Canada
-
Investigational Site Number : 1240010
Edmonton, Alberta, T5J 3S9, Canada
-
Investigational Site Number : 3920001
Yokohama, Kanagawa, 232-8555, Japan
-
Investigational Site Number : 3920002
Tsu, Mie-ken, 514-0125, Japan
-
Monroe Carell Jr. Childrens Hospital at Vanderbilt- Site Number : 8400005
Nashville, Tennessee, 37232, United States
-
Pediatric Dermatology of Miami Site Number : 8400015
Coral Gables, Florida, 33146, United States
-
Treasure Valley Medical Research Site Number : 8400019
Boise, Idaho, 83706, United States
-
Vital Prospects Clinical Research Institute, P.C.- Site Number : 8400002
Tulsa, Oklahoma, 74136, United States
-
Washington University School of Medicine- Site Number : 8400004
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.